Tisagenlecleucel Approved in Europe for DLBCL, ALL

August 27, 2018 – The European Commission has approved tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma (DLBCL) that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse posttransplant, or in second or later relapse, according to Novartis, the manufacturer of the CAR T-cell therapy. The approval in DLBCL … (leggi tutto)